1stOncology™: Cancer Intelligence Service – Page 9080 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021

On July 7, 2021 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported that it will report its second quarter 2021 financial and operating results on Thursday, August 5, 2021, before the U.S. financial markets open (Press release, Regeneron, JUL 7, 2021, View Source [SID1234584659]). The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Conference Call Information
To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International), conference ID 9098036. A link to the webcast may be accessed from the ‘Investors and Media’ page of Regeneron’s website at View Source A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.

Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

On July 7, 2021 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, reported that management will present at the Ladenburg Thalmann Healthcare Conference being held in a virtual setting on Wednesday, July 14, 2021 at 10:00am ET (Press release, Protara Therapeutics, JUL 7, 2021, View Source [SID1234584658]).

A webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: View Source The webcast will be archived on the Company’s website for 90 days following the presentation.

Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th

On July 7, 2021 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that it will participate in a Fireside Chat with H.C. Wainwright at 11 a.m. Eastern Time on Monday, July 12, 2021 (Press release, Phio Pharmaceuticals, JUL 7, 2021, View Source [SID1234584657]).

Interested parties are asked to register ahead of time in order to listen to the live event at (click here) or through the "Investors – Events and Presentations" section of the Company’s website. The webcast will be archived and available on the Company’s website for 90 days.

Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021

On July 7, 2021 Kinnate Biopharma Inc. (Nasdaq: KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, reported that its Chief Executive Officer Nima Farzan will participate in the William Blair Biotech Focus Conference 2021, being held virtually from July 14-15, 2021 (Press release, Kinnate Biopharma, JUL 7, 2021, View Source [SID1234584656]).

Event: William Blair Biotech Focus Conference 2021
Panel: "Next Generation Small Molecules in Oncology"
Location: Virtual
Date: Thursday, July 15, 2021
Time: 9:00 AM ET/ 6:00 AM PT

Members of the Kinnate management team will also host investor meetings during the conference.

A live webcast of the William Blair panel discussion will be available in the Investors and Media section of the Kinnate website at www.kinnate.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.

South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology

On July 6, 2021 The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre reported that they have entered into a license agreement granting worldwide exclusive rights to Pierre Fabre to develop and commercialize a family of human antibodies generated through the phage display human antibody Ymax-ABL library owned by Y-Biologics (Press release, Pierre Fabre, JUL 6, 2021, View Source [SID1234584653]).

These antibodies have been functionally validated by the Pierre Fabre R&D teams for their specific properties on a pivotal immuno-oncology target acting on the tumoral microenvironment. Pierre Fabre intends to select a new therapeutic candidate in immuno-oncology for further developments.

This licensing agreement results from the strong and now proven complementarity between the two companies who have been collaborating since 2018. The final objective pursued by Y-Biologics and Pierre Fabre is to provide patients with innovative drugs to target refractory or relapsing cancer, taking advantage of the immune infiltrate to inhibit the growth of tumor cells.

This new milestone reached by the two companies reveals the effectiveness of the scientific means put in place by Y-Biologics, associated with the high expertise of Pierre Fabre in oncology.

Young Woo Park, CEO of Y-Biologics, stated: "We are very pleased to sign our first license agreement with Pierre Fabre. The collaboration between Y-Biologics and Pierre Fabre which is being conducted based on mutual trust, is expected to further advance the development of innovative immuno-oncology therapeutics targeting the tumor microenvironment."

"Since the beginning of our partnership, the collaboration with Y-Biologics has been very efficient and fruitful. Their library has allowed us to identify a family of human antibodies against a promising target defined by our researchers at our dedicated Center of Immunology. This new exciting license agreement will allow us to further support the development of this therapy for the benefit of patients," added Nathalie Corvaïa, Head of Immuno-Oncology Research, Center of Immunology Pierre Fabre (CIPF).